Oral GLP-1 Therapies and the Next Phase of Metabolic Disease Management

Oral GLP-1 Therapies and the Next Phase of Metabolic Disease Management

Implications for Utilization Management Strategy for Health Plans

By Kathryn Kolonic, DO, MBA, MPH, CPHQ 

Oral GLP-1 therapies are reshaping metabolic disease management, and the implications for health plans extend far beyond pharmacy cost. As oral formulations lower the barrier to treatment initiation, utilization is poised to expand substantially across broader patient populations. Traditional prior authorization approaches were built for therapies with high initiation barriers and controlled uptake, and they may no longer be sufficient to manage the demand ahead.

In our latest whitepaper, Oral GLP-1 Therapies and the Next Phase of Metabolic Disease Management, you'll find: 

  • Why the shift from injectable to oral GLP-1s is a structural change in utilization

  • How expanded adoption could increase total spend even as per-patient costs decline

  • Where current prior authorization approaches fall short

  • A strategic framework that links coverage to measurable outcomes

Access the whitepaper by completing the form below.